Caliway Biopharmaceuticals Co. L
6919
Rank in Stocks
#4342
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Share Price
$2.29
Market Cap
$3.56B
Change (1 day)
-2.50%
Change (1 year)
-57.22%
Country
TW
Trade Caliway Biopharmaceuticals Co. L (6919)
Category
Healthcare
Number of shares outstanding for Caliway Biopharmaceuticals Co. L (6919)
Number of shares outstanding as of October 2026: 0
According to Caliway Biopharmaceuticals Co. L latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of October 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Caliway Biopharmaceuticals Co. L (6919) from 2019 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2025 | 1.54B | 7.93% |
| 2024 | 1.43B | 15.40% |
| 2023 | 1.24B | 5.77% |
| 2022 | 1.17B | 27.35% |
| 2021 | 919.74M | 23.49% |
| 2020 | 744.76M | 6.52% |
| 2019 | 699.18M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 62.19M | - |
NL
|
|
| - | - |
CH
|
